One potential mechanism for the growth-promoting effect of integrin v6 may be enhanced MMP-9 activity. and SW480 cells. The effects of cell density on Efavirenz v6 expression and MMP-9 secretion were also detected by Biotrak MMP-9 activity assay and gelatin zymography assay. High cell density evidently enhanced v6 expression and promoted MMP-9 secretion compared with low density. CONCLUSION: Integrin v6 sustains and promotes tumor invasive growth in tumor progression a self-perpetuating mechanism. Integrin 6-mediated MMP-9 secretion facilitates pericellular matrix degradation at Efavirenz high cell density, which provides the basis of invasive growth. a self-perpetuating mechanism. Integrin 6-mediated matrix metalloproteinase-9 secretion facilitates pericellular matrix degradation at high cell density, which provides the basis of invasive growth. INTRODUCTION Invasive growth is one of the main features that distinguish malignant tumor cells from normal cells. The mechanisms by which tumor cells escape the growth constraints imposed on normal cells by cell crowding and dense pericellular circumstance are controversial. The reason why colon cancer cells sustain invasive growth a self-perpetuating manner in tumor progression is also unclear. There is a general consensus, nevertheless, that this demonstrates a cell-surface problem, and the cell adhesion molecules integrin v6 and matrix metalloproteinase-9 (MMP-9) are likely to be involved in tumor progression[1,2]. Within the integrin v subfamily, integrin v6 is expressed only on abnormal epithelial cells. It is highly expressed during morphogenesis and tumorigenesis[2-4], and expression has been observed at the margins of advanced colon tumors. One potential mechanism for the growth-promoting effect of integrin v6 may be enhanced MMP-9 activity. The invasive growth of colon cancer cells is also likely to reflect the ability of tumor cells to digest their surrounding matrix scaffold through the secretion of MMP-9 because integrin v6 expression in colon cancer cells has been shown by our group to induce MMP-9 secretion[5], and the inhibition of MMP-9 activity abolishes the integrin v6-mediated growth effect[6]. As an adhesion protein involved in both the nuclear Wnt/beta-catenin pathway and the mesenchymal transition of colorectal cancer cells, nuclear beta-catenin expression increases from the central area towards the invasive margin. It has been reported that the expression of integrin v6, which is also an adhesion protein, is induced during the epithelial-transition of aggressive colon carcinoma[3,7-9]. MMP-9 overexpression related to tumor invasive growth in gastric carcinoma has also been reported. The induction of MMP-9 mRNA in endothelial cells has been reported to be dependent on direct cell adhesion with cancer cells[10]. The Rabbit Polyclonal to REN maximal expression of MMPs has also been displayed at the invasive margin of colon tumor cell islands. This finding is consistent with the observation that integrin v6 preferentially localizes at the leading edge of epithelial ovarian cancer with a malignant potential of invasiveness and metastasis. The consequence of integrin 6-mediated MMP-9 secretion may provide the basis for a self-perpetuating system of tumor invasive growth that operates through integrin 6. However, the effects of both integrin v6 and MMP-9 on invasive growth in colon cancer progression remain controversial. This study was designed to identify the mechanisms by which integrin v6 sustains and promotes tumor invasive growth in colon cancer progression. MATERIALS AND METHODS Cell lines and culture conditions The human colon cancer cell lines WiDr and SW480 and the normal human keratinocyte cell line HaCaT were obtained from the ATCC (Rockville, MD, United States). SW480 cells, which lack constitutive integrin v6 expression, were stably transfected with pcDNA1neo constructs that contained either the gene construct or the expression plasmid only (SW480 6 or SW480 mock) as previously described[11]. For flow cytometry analysis, low-density cultures were established by seeding 5 to 7.5 105 Efavirenz cells in 2.5 mL of standard medium into 6 cm-diameter tissue culture dishes or 25 cm2 tissue culture flasks. High density cultures were established using identical cell numbers and medium volume seeded into 24-well tissue culture plates (Falcon Becton Dickinson, Oxnard, CA). At 72 h, the low- and high-density cultures were approximately 40% and 100% confluent, respectively. Then, cells were harvested by trypsin/EDTA at 72 h for the assessment of integrin 6 expression. The ratio of cell number to surface area was in the range of 1 1.5 to 2 105 cells/cm2 and 3.5 to 4 105 cells/cm2 for the low- and high-density cultures, respectively. Antibodies and reagents The anti-integrin v6 mAb 2G2 was obtained from Biogen, and the specificity of the antibody has previously been reported[12]. FITC-conjugated goat-anti-mouse IgG was obtained from Jackson (ImmunoResearch Laboratories, Inc., United States); anti-MMP9 mAbs-whole molecule (ab38898, Abcam, United Kingdom) was purchased from Jingmei Biotech (Shenzhen,.